SELMA ROSA: Open Payments
NPI 1457930158 · NEWINGTON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$295 in 12 payments from 9 companies in 2025. Trend: 2023 $328 · 2024 $48 · 2025 $295
Food & beverage: $295
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 2 | $47 |
| Neurocrine BioSciences, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| REVANCE THERAPEUTICS, INC. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $34 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Solta Medical, a division of Bausch Health US, LLC | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
Products named: REXULTI, ARISTADA, TRINTELLIX, DAXXIFY, CAPLYTA, Auvelity, INGREZZA.
Industry payments across CT — which companies pay providers there.
